UNICREDIT BANK/CALL/ELI LILLY & CO/1000/0.1/18.06.25 | Real-time BOERSE MUENCHEN 15:42:22 2024-07-02 EDT | ||
| 8.74 EUR | -2.24% |
|
| Current month | +1.13% | ||
| 1 month | +59.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 8.74 | -2.24% |
| 24-07-01 | 8.94 | +1.13% |
| 24-06-28 | 8.84 | +2.79% |
| 24-06-27 | 8.6 | +2.26% |
| 24-06-26 | 8.41 | -1.98% |
Real-time BOERSE MUENCHEN
Last update July 02, 2024 at 03:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC96HD |
| ISIN | DE000HC96HD3 |
| Date issued | 2023-09-11 |
| Strike | 1,000 $ |
| Maturity | 2025-06-18 (351 Days) |
| Parity | 10 : 1 |
| Emission price | 1.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.94 € |
|---|---|
| Lowest since issue | 0.83 € |
| Spread | 0.15 € |
| Spread % | 1.69% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Warrants
- Warrant
